Blackstone announced it closed its Blackstone Life Sciences VI fund at $6.3 billion, the largest life sciences private investment vehicle it has raised. The new fund is nearly 40% larger than the $4.6 billion predecessor completed in 2020 and adds further scale to the firm’s BXLS platform launched in 2018. Blackstone said partnerships within the platform have produced 34 approved innovative medicines and devices, and it highlighted an 86% approval rate for late-stage assets managed in the franchise, above the drug industry average. The platform has increasingly backed royalties and late-stage clinical development assets, supporting investments connected to major biopharma and medtech portfolios. The record close comes as investors continue to seek exposure to commercially validated biotech outcomes, including royalty structures tied to pipeline progress and regulatory milestones. Blackstone previously committed capital to Teva drug development and to Merck’s Terns deal structure. The fund closure signals continued institutional appetite for diversified life sciences exposure and reinforces the role of large private capital pools in funding translational and late-stage clinical risk.